Geode Capital Management’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
Geode Capital Management's LUCD Position: Q2 2026 in Review
Geode Capital Management increased its Lucid Diagnostics (LUCD) stake by 69% in Q2 2026, buying an estimated $1.66M and bringing the position to 3,789,948 shares worth $4.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3000.
Geode Capital Management first reported a position in LUCD in Q4 2021 and has held it in 19 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- Geode Capital Management held 3,789,948 shares of Lucid Diagnostics worth $4.06M as of Q2 2026.
- Geode Capital Management bought 1,544,598 Lucid Diagnostics shares in Q2 2026, an estimated $1.66M.
- Lucid Diagnostics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3000 holding.
- Geode Capital Management first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 19 quarters since.
- 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.